Copyright
©The Author(s) 2021.
World J Hepatol. Jan 27, 2022; 14(1): 98-118
Published online Jan 27, 2022. doi: 10.4254/wjh.v14.i1.98
Published online Jan 27, 2022. doi: 10.4254/wjh.v14.i1.98
Figure 2 Immunohistochemistry of progressive familial intrahepatic cholestasis type 2 and 3.
A: Normal liver showing canalicular bile salt exporter pump (BSEP) immunostaining; B: Faint BSEP immunostaining in a case of progressive familial intrahepatic cholestasis (PFIC2); C: Normal Liver showing canalicular multidrug resistant protein-3 (MDR3) immunostaining; D: Faint or absent MDR3 immunostaining in a case of PFIC3.
- Citation: Alam S, Lal BB. Recent updates on progressive familial intrahepatic cholestasis types 1, 2 and 3: Outcome and therapeutic strategies. World J Hepatol 2022; 14(1): 98-118
- URL: https://www.wjgnet.com/1948-5182/full/v14/i1/98.htm
- DOI: https://dx.doi.org/10.4254/wjh.v14.i1.98